Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Payables (2016 - 2025)

Medifast's Payables history spans 16 years, with the latest figure at $38.4 million for Q4 2025.

  • For Q4 2025, Payables fell 32.1% year-over-year to $38.4 million; the TTM value through Dec 2025 reached $38.4 million, down 32.1%, while the annual FY2025 figure was $38.4 million, 32.1% down from the prior year.
  • Payables reached $38.4 million in Q4 2025 per MED's latest filing, down from $41.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $174.4 million in Q1 2022 to a low of $38.4 million in Q4 2025.
  • Average Payables over 5 years is $103.2 million, with a median of $104.2 million recorded in 2023.
  • Peak YoY movement for Payables: surged 79.74% in 2021, then plummeted 41.78% in 2025.
  • A 5-year view of Payables shows it stood at $163.3 million in 2021, then decreased by 17.52% to $134.7 million in 2022, then plummeted by 35.84% to $86.4 million in 2023, then tumbled by 34.62% to $56.5 million in 2024, then tumbled by 32.1% to $38.4 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Payables are $38.4 million (Q4 2025), $41.2 million (Q3 2025), and $40.3 million (Q2 2025).